Leerink Partnrs Comments on Xeris Biopharma Q3 Earnings

Key Points

• Analysts at Leerink Partners have revised Xeris Biopharma's Q3 2025 earnings per share (EPS) estimate down to $0.01, reflecting a decrease from the previous estimate of $0.02.
• The company reported a Q2 EPS of ($0.01), surpassing analysts' consensus estimates of ($0.03), with revenue of $67.71 million compared to expectations of $64.58 million.
• Xeris Biopharma has received a consensus rating of "Moderate Buy" with a price target of $6.58 from analysts, indicating positive sentiment despite recent EPS adjustments.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for shares of Xeris Biopharma in a report released on Tuesday, August 19th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share.

XERS has been the subject of a number of other research reports. Leerink Partners lifted their target price on Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a report on Tuesday, August 19th. HC Wainwright initiated coverage on Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price for the company. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Oppenheimer boosted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.08.

Xeris Biopharma Price Performance

XERS stock traded up $0.19 during mid-day trading on Thursday, reaching $7.96. 774,030 shares of the company traded hands, compared to its average volume of 2,541,736. The company has a market capitalization of $1.28 billion, a P/E ratio of -37.74 and a beta of 0.65. Xeris Biopharma has a 52-week low of $2.48 and a 52-week high of $8.02. The company has a fifty day moving average price of $5.60 and a 200-day moving average price of $4.89.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Xeris Biopharma by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock worth $44,522,000 after buying an additional 210,581 shares during the last quarter. Geode Capital Management LLC lifted its position in Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock worth $17,052,000 after buying an additional 244,862 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock worth $14,429,000 after buying an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after buying an additional 369,420 shares during the last quarter. Institutional investors own 42.75% of the company's stock.

Insider Transactions at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the completion of the transaction, the director owned 115,000 shares of the company's stock, valued at approximately $837,200. The trade was a 26.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Johnson sold 107,500 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the transaction, the director directly owned 833,483 shares of the company's stock, valued at $6,101,095.56. The trade was a 11.42% decrease in their position. The disclosure for this sale can be found here. 4.56% of the stock is owned by insiders.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.